Kate is Managing Partner at SVLS and is based in London.
Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Affinium, Alantos, Auxilium, Convergence, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, MedNova, Micromet, Oncoethix, PowderMed, RespiVert and Vantia and current investments including Atopix, Autifony, Bicycle, Calchan, Kalvista, Karus, Kesios, Pulmocide, TopiVert and VHSquared. Kate has played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee as well as the Investment Committees for all SV’s funds. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).
Dan was founder, President and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company. Previously Dan was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials; the drug was acquired by Aptalis, Inc. in 2011. Dan has also held senior executive positions at a number of other biotechnology companies. He served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion. Dan holds the following external Board seats: Nabriva Therapeutics (Chairman, NASDAQ:NBRV), Atox Bio (Chairman), Cidara Therapeutics (NASDAQ: CDTX) and Arbutus Biopharma (NASDAQ: ABUS). He is also Chairman of Biocom, the life science industry association of California that represents more than 800 member companies.
Dan is a graduate of Stanford University (AB, Economics) and Harvard Business School (MBA).
Non Executive Director
Matthew is a partner at SR One in London.
Matthew joined SR One’s London office in 2011. Previously he was a Vice President at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York. His portfolio companies include Asceneuron, AtoxBio, Progenitor, PsiOxus, Puridify and VHSquared.
Matthew studied Molecular Biology at The University of Oxford; Drug Discovery at UCL; Corporate Finance at The London Business School and holds various FSA & SEC qualifications
Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve currently serves as Chairman of the Board of Directors for Forum Pharmaceuticals (formerly EnVivo Pharmaceuticals) and serves on the Board of Directors of Innovent Biologics, Proteostasis Therapeutics, Iora Health, Pulmocide, Semma Therapeutics and Denali Therapeutics. Steve previously served on the boards of several private and public health care companies including, Blueprint Medicines (NASDAQ: BPMC) FoldRx Pharmaceuticals (acquired by Pfizer), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), and Respivert, Ltd (acquired by J&J).
Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.
Dr. MacLaughlin joined Johnson & Johnson Development Corporation (JJDC) in May 2020 as Senior Director, Venture Investments, and is based in London, UK at the Johnson & Johnson Innovation Centre. She brings >20 years of experience in Life Sciences, in particular founding companies and financing early stage life science technologies. Fiona’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.
Previously she was a Director at Inkef Capital where she led investments in and sat on the Boards of a number of portfolio companies. Before that, Fiona was an Associate at Advent Life Sciences, during which time she co-founded Boston-based Arrakis Therapeutics Inc and helped build a number of early stage companies. Her interest in innovation came from her prior role as a Business Development Manager in the Technology Transfer Division of the Wellcome Trust. There she evaluated early stage product development opportunities and investments for Translational Funding, established and ran the £45M “R&D for Affordable Healthcare” fund, a joint venture with the Indian Government supporting development of new technologies in India, and was part of the founding team with Merck & Co Inc, a joint venture leading to the formation of the Hilleman Laboratories, Delhi. Prior to joining Wellcome, Fiona was held senior operational roles in a number of biotech/medtech companies. She is a Pharmacist by training and has a PhD in drug delivery (Nottingham University).
Pete is Pulmocide’s Chief Scientific Officer. The majority of Pete’s pharmaceutical industry career between 1980 and 2003 was spent at Glaxo PLC, GlaxoWellcome and GlaxoSmithKline with a focus on respiratory drug discovery and development. Pete co-foundedr Respivert with Garth Rapeport and colleagues in 2007. Following the acquisition in 2010 by Centocor Ortho Biotech, Pete was a member of the small team which licensed the appropriate Respivert intellectual property rights to Topivert Ltd, leading to the successful Series A funding of that company.
Sam is Managing Partner, Life Sciences, at IPGroup.
Sam has over 20 years’ experience in the biotechnology industry, both as a top-ranked equity analyst in the City and, subsequently, as an investor and chief executive. He is Founder and Executive Chairman of Istesso Limited, a Phase 2 drug-discovery company, and oversees the Life Sciences portfolio for the FTSE250 company IP Group plc. He serves as a non-executive director of Diurnal Group plc, Microbiotica Ltd, Psioxus Ltd and Kuur Therapeutics Ltd. Sam holds a PhD in molecular biology from Cambridge and a degree in biology from Oxford.
Rich is co-founder and General Partner of Longwood Fund and has spent approximately 35 years as a life sciences entrepreneur and investor. Mr. Aldrich co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline); Concert Pharmaceuticals NASDAQ: CNCE), where he serves as Chair of the Board; and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), Axial Biotherapeutics, and TScan Therapeutics. Mr. Aldrich also serves as a Director of Longwood portfolio companies Axial, Renovia, and Sitryx Therapeutics. Prior to co-founding Longwood, Mr. Aldrich co-founded RA Capital Management, LLC, a life sciences investment fund, in which he remains an investor. Prior to founding RA Capital Management, LLC, Mr. Aldrich was a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX), a $45 billion company, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth College.
Dalton is the Director of Ashahi Kasei Pharmaceuticals Corporate Venture Capital fund. He joined Asahi Kasei Group in 2018. Dalton has over 25 years of life sciences experience, including marketing, new product commercialization and business development roles at Roche, Daiichi-Sankyo and Novo Nordisk. He began his venture career at Latterell Venture Partners, and was later an investor at Johnson & Johnson Development Corp. He is currently a board observer at Pulmocide, Glycomine and AtoxBio.
Debbie joined SR One in 2005 to establish the European investment office with a background in drug development and licensing gained through numerous prior roles held in clinical development, medical affairs and business development with Merrell Dow, SmithKline Beecham and GSK. Debbie is also an independent director on the board of Cancer Research Technology, the commercialization arm of Cancer Research UK and a member of the Advisory Board of the University of Cambridge Maxwell Centre’s ‘Impulse’ program for young entrepreneurs.